Skip to main content
SpringerLink
Log in

New milrinone analogues: in vitro study of structure-activity relationships for positive inotropic effect, antagonism towards endogenous adenosine, and inhibition of cardiac type III phosphodiesterase

  • Original Article
  • Published:
Naunyn-Schmiedeberg's Archives of Pharmacology Aims and scope Submit manuscript

Abstract.

Two mechanisms are responsible for the positive inotropic effect of the cardiotonic drug milrinone, i.e., inhibition of type III cAMP phosphodiesterase (PDE III), and displacement of endogenous adenosine from A1 inhibitory receptor. Since PDE III inhibition may increase the likelihood of cardiac arrhythmias by increasing cAMP content, our attention focused on the synthesis of new compounds with more pronounced characteristics as adenosine antagonists.

In this work, four new milrinone analogues were studied, in comparison with the parent drug, for their effects on the contractility of guinea pig isolated atrial preparations, their ability to antagonize endogenous adenosine at the level of A1 receptor, and to inhibit the activity of PDE III partially purified from guinea pig heart. The new compounds present various chemical substitutions with respect to the parent drug: in compounds SF397 (methyl 5-cyano-2-methyl-6-oxo-1,6-dihydropyridine-3-carboxylate) and SF399 (benzyl 5-cyano-2-methyl-6-oxo-1,6-dihydropyridine-3-carboxylate), the 4-pyridil moiety of milrinone was replaced with a methoxycarbonyl and a benzyloxycarbonyl group, respectively; the same structural modifications were also associated with the replacement of the cyano-group in 5-position with an acetyl group in compounds SF416 (methyl 5-acetyl-2-methyl-6-oxo-1,6-dihydropyridine-3-carboxylate) and SF419 (benzyl 5-acetyl-2-methyl-6-oxo-1,6-dihydropyridine-3-carboxylate).

All the new compounds had a marked positive inotropic effect, most of them also being more active and more potent than milrinone. When their affinity for A1 receptor was assessed as the displacement of [3H] 8-cyclopentyl-1,3-dipropylxanthine ([3H]DPCPX) from cardiac membranes, SF397 and SF399 showed affinity (Ki of about 600 nM) similar to that of milrinone (Ki 550 nM). By contrast, SF416 and SF419 had very low (Ki of about 10,000 nM) or scarce (Ki of about 2,000 nM) anti-adenosine component, respectively. All the new compounds inhibited PDE III activity, their Ki values proceeding in the following order: milrinone (3.80 μM) <SF397 (7.00 μM) <SF399 (8.80 μM) <SF416 (35.00 μM) SF419< (155.00 μM). To better characterize the mechanisms responsible for the positive inotropic response of the new compounds, we also investigated the effects of new analogues on some systems (ATP-dependent Ca2+ uptake, Ca2+ATPase, Na+/K+ATPase, Na+/Ca2+ exchange carrier) or a receptor (β-adrenoceptor) mainly involved in the control of cardiac contractility. None of the tested compounds inhibited enzyme or transport systems; however, SF397, SF399 and SF416, although to different extents, had a direct β-adrenergic action. Indications about structure-activity relationships are tentatively discussed, in order to obtain useful information for the design of new analogues with better pharmacological profiles.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1.
Fig. 2.
Fig. 3.

Similar content being viewed by others

References

  • Alousi AA, Farah AE (1980) Letter to the editor. Circ Res 46:887–888

    PubMed  Google Scholar 

  • Alousi AA, Farah AE, Lesher GY, Opalka CJ Jr (1979) Cardiotonic activity of amrinone-WIN 40680 (5'-amino-3,4'-bipyridin 6(1H)-one. Circ Res 45:666–677

    CAS  PubMed  Google Scholar 

  • Belardinelli L, Isenberg G (1983) Isolated atrial myocytes: adenosine and acetylcholine increase potassium conductance. Am J Physiol 244:H734−H737

    CAS  PubMed  Google Scholar 

  • Carpenedo F, Floreani M, Cargnelli G (1984) Competitive inhibition of phosphodiesterase activity by amrinone: its implication in the cardiac effect of the drug. Pharmacol Res Commun 16:969–977

    Google Scholar 

  • Cheng JC, Prusoff WH (1973) Relationship between the inhibition constant (Ki) and the concentration of inhibitor that causes 50 percent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22:3099–3108

    CAS  PubMed  Google Scholar 

  • Dixon M (1953) The determination of enzyme inhibitor constants. Biochem J 55:170–171

    CAS  Google Scholar 

  • Dorigo P, Maragno I (1986) Interaction of amrinone with endogenous adenosine in guinea pig atria. Br J Pharmacol 87:623–629

    CAS  PubMed  Google Scholar 

  • Dorigo P, Gaion RM, Maragno I (1990) Involvement of purine compounds in the inotropic action of milrinone. Cardiovasc Drugs Ther 4:509–514

    CAS  PubMed  Google Scholar 

  • Dorigo P, Gaion RM, Belluco P, Mosti L, Borea PA, Maragno I (1991) An analysis of the mechanisms of the inotropic action of some milrinone analogues in guinea pig isolated atria. Br J Pharmacol 104:867–872

    CAS  PubMed  Google Scholar 

  • Dorigo P, Gaion RM, Belluco P, Borea PA, Guerra L, Mosti L, Floreani M, Carpenedo F (1992) Antagonism toward endogenous adenosine and inhibition of cGI-PDE in the cardiac effects of amrinone, milrinone and related analogues. Gen Pharmacol 23:535–541

    Article  CAS  PubMed  Google Scholar 

  • Dorigo P, Gaion RM, Belluco P, Fraccarollo D, Maragno I, Bombieri G, Benetollo F, Mosti L, Orsini F (1993) A pharmacological, crystallographic, and quantum chemical study of new inotropic agents. J Med Chem 36:2475–2484

    CAS  PubMed  Google Scholar 

  • Dorigo P, Fraccarollo D, Santostasi G, Maragno I, Floreani M, Borea PA, Mosti L, Sansebastiano L, Fossa P, Orsini F, Benetollo F, Bombieri G (1996) Synthesis and cardiotonic activity of novel pyrimidine derivatives. Crystallographic and quantum chemical studies. J Med Chem 39:3671–3683

    Article  CAS  PubMed  Google Scholar 

  • Dorigo P, Fraccarollo D, Gaion RM, Santostasi G, Borea PA, Floreani M, Mosti L, Maragno I (1997) New inotropic agents: milrinone analogues. Gen Pharmacol 28:781–788

    Article  CAS  PubMed  Google Scholar 

  • Earl CQ, Linden J, Weglicki WB (1986) Biochemical mechanisms for the inotropic effect of the cardiotonic drug milrinone. J Cardiovasc Pharmacol 8:864–872

    CAS  PubMed  Google Scholar 

  • Endoh M (1979) Correlation of cyclic AMP and cyclic GMP levels with changes in contractile force of dog ventricular myocardium during cholinergic antagonism of positive actions of histamine, glucagon, theophylline and papaverine. Jpn J Pharmacol 29:855–864

    CAS  PubMed  Google Scholar 

  • Endoh M (2002) Mechanisms of action of novel cardiotonic agents. J Cardiovasc Pharmacol 40:323–338

    CAS  PubMed  Google Scholar 

  • Endoh M, Yamashita S, Taira N (1982) Positive inotropic effect of amrinone in relation to cyclic nucleotide metabolism in the canine ventricular muscle. J Pharmacol Exp Ther 221:775–783

    CAS  PubMed  Google Scholar 

  • Endoh M, Yamashita S, Taira N, Blinks J (1986) Effects of new inotropic agents on cyclic nucleotide metabolism and calcium transient in canine muscle. Circulation 73 [Suppl 3]:117–133

    Google Scholar 

  • Farah AE, Alousi AA (1978) New cardiotonic agents: a search for digitalis substitute. Life Sci 22:1139–1148

    Article  CAS  PubMed  Google Scholar 

  • Floreani M, Forlin A, Pandolfo L, Petrone M, Bellin S (1996) Mechanisms of plumbagin action on guinea pig isolated atria. J Pharmacol Exp Ther 278:763–770

    CAS  PubMed  Google Scholar 

  • Floreani M, Borea PA, Gessi S, Mosti L, Fossa P, Dorigo P (1997) A new milrinone analog: role of binding to A1 adenosine receptor in its positive inotropic effect on isolated guinea pig and rat atria. J Pharmacol Exp Ther 283:541–547

    CAS  PubMed  Google Scholar 

  • Fossa P, Boggia R, Lo Presti E, Mosti L, Dorigo P, Floreani M (1997) Inotropic agents: synthesis and structure-activity relationships of new milrinone related cAMP PDE III inhibitors. Farmaco 52:523–530

    CAS  PubMed  Google Scholar 

  • Fossa P, Boggia R, Mosti L (1998) Toward the identification of the cardiac cGMP inhibited-phosphodiesterase catalytic site. J Comput Aided Mol Des 12:361–372

    Article  CAS  PubMed  Google Scholar 

  • Honerjäger P, Schäfer-Korting M, Reiter M (1981) Involvement of cyclic AMP in the direct inotropic action of amrinone: biochemical and functional evidence. Naunyn-Schmiedebergs Arch Pharmacol 318:112–120

    Google Scholar 

  • Ito M, Tanaka T, Saitoh M, Masuoka H, Nakano T, Hidaka H (1988) Selective inhibition of cyclic AMP phosphodiesterases from various human tissues by milrinone, a potent cardiac bipyridine. Biochem Pharmacol 37:2041–2044

    Article  CAS  PubMed  Google Scholar 

  • Jones RL, Besch HR Jr, Watanabe AM (1977) Monovalent cation stimulation of Ca2+ uptake by cardiac membrane vesicles. J Biol Chem 252:3315–3323

    CAS  PubMed  Google Scholar 

  • Kobylarz DC, Steffen RP, Weishaar RE, Evans DB (1985) Relationship between inhibition of ventricular peak III phosphodiesterase and the in vivo cardiotonic effect of CI−914 in several species. Pharmacologist 27:603–609

    Google Scholar 

  • Lathers CM, Roberts J (1980) Digitalis cardiotoxicity revisited. Life Sci 27:1713–1733

    Article  CAS  PubMed  Google Scholar 

  • Lowry OH, Rosebrough NJ, Farr, AL, Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265–275

    CAS  Google Scholar 

  • Lubbe WF, Podzuwett T, Opie LH (1992) Potential arrhythmogenic role of cyclic monophosphate (AMP) and cytosolic calcium overload: implications for prophylactic effects of beta-blockers in myocardial infarction and proarrhythmic effects of phosphodiesterase inhibitors. J Am Cell Cardiol 19:1622–1655

    CAS  Google Scholar 

  • Mason DT, Zelis R, Lee G, Hughes JL, Spann JF, Amsterdam EA (1971) Current concepts and treatment of digitalis toxicity. Am J Cardiol 27:546–559

    CAS  PubMed  Google Scholar 

  • Massie BM (1998) 15 years of heart-failure trials what have we learned. Lancet 352:St29−St33

    Google Scholar 

  • Menozzi G, Mosti L, Schenone P (1987) Reaction of 2-dimethylaminomethylene-1,3-diones with nucleophiles. VI. Synthesis of ethyl or methyl-disubstituted 1-H-pyrazole-4-carboxylates. J Heterocycl Chem 24:1669–1675

    CAS  Google Scholar 

  • Miller RR, Palomo AR, Brandon BS, Hartley CJ, Quinones MA (1981) Combined vasodilator and iotropic therapy of heart failure: experimental and clinical concepts. Am Heart J 102:500–508

    CAS  PubMed  Google Scholar 

  • Moos WH, Humblet CC, Sircar I, Rithner C, Weishaar RE, Bristol JA, McPhail AT (1987) Cardiotonic agents. (Selective inhibitors of adenosine 3',5'-cyclic phosphate phosphodiesterase III. Elaboration of a five-point model for positive inotropic activity. J Med Chem 30:1963–1972

    CAS  PubMed  Google Scholar 

  • Munson PJ, Rodbard D (1980) Ligand: a versatile computerized approach for the characterization of ligand binding systems. Anal Biochem 107:220–239

    CAS  PubMed  Google Scholar 

  • Nicholson CD, Challis RAJ, Shahid M (1991) Differential modulation of tissue function and therapeutic potential of selective inhibitors of cyclic nucleotide phosphodiesterase isoenzymes. Trends Pharmacol Sci 12:19–27

    CAS  PubMed  Google Scholar 

  • Reiter M (1972) Drugs and heart muscle. Ann Rev Pharmacol 12:111–124

    CAS  Google Scholar 

  • Skomedal T, Schlander I, Aass H, Osnes JB (1988) Properties of the inotropic response in rat papillary muscle to the dihydropyridine Ca-channel activator BAYK8644. Pharmacol Toxicol 63:20–25

    CAS  PubMed  Google Scholar 

  • Silver PJ, Harris AL, Fort DJ, Perrone MH, Evans DB (1987) Effects of the cardiotonic/vasodilator agents amrinone and milrinone on phosphodiesterase (PDE) isoenzymes and contractile force in guinea pig cardiac and vascular tissue. Fedn Proc 46:373

    Google Scholar 

  • Slaughter RS, Sutko JL, Reeves JP (1983) Equilibrium calcium-calcium exchange in cardiac sarcolemmal vesicles. J Biol Chem 258:3183–3190

    CAS  PubMed  Google Scholar 

  • Taylor SH, Silke B, Nelson GJC (1982) Principles of treatment of left ventricular failure. Eur Heart J 3:19–43

    Google Scholar 

  • Thompson WJ, Brooker G, Appleman MM (1974) Assay of cyclic nucleotide phosphodiesterase with radioactive substrates. Meth Enzymol 38:205–214

    CAS  PubMed  Google Scholar 

  • Tsien RW (1977) Cyclic AMP and contractile activity in heart. Adv Cyclic Nucl Res 8:363–420

    Google Scholar 

  • Ward A, Brodgen RN, Heel RC, Speight TM, Avery GS (1983) Amrinone: a preliminary review of its pharmacological properties and therapeutic use. Drugs 26:468–502

    CAS  PubMed  Google Scholar 

  • Weishaar RE, Burrows SD, Kobylarz DC, Quade MM, Evans DB (1986) Multiple molecular forms of cyclic nucleotide phosphodiesterase in cardiac and smooth muscle and in platelets. Biochem Pharmacol 35:787–800

    CAS  PubMed  Google Scholar 

  • Weishaar RE, Kobylarz-Singer DL, Steffen RP, Kaplan AR (1987) Subclasses of cyclic AMP specific phosphodiesterase in left ventricular muscle and their involvement in regulating myocardial contractility. Circ Res 61:539–547

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements.

This work was supported by grants from MIUR (Ministero dell'Istruzione, dell'Università e della Ricerca, Italy). The experiments reported here were conducted in accordance with the Italian law on experimental use of animals. The experiments were supervised by a veterinary committee to ensure animal care and comfort.

Author information

Authors and Affiliations

  1. Dipartimento di Farmacologia e Anestesiologia, Sezione di Farmacologia, Università di Padova, 35131, Padova, Italy

    M. Floreani & P. Dorigo

  2. Dipartimento di Scienze Farmaceutiche, Università di Genova, 16100 , Genova, Italy

    P. Fossa & L. Mosti

  3. Dipartimento di Medicina Clinica e Sperimentale, Unità di Farmacologia, Università di Ferrara, 44100, Ferrara, Italy

    S. Gessi & P. A. Borea

Authors
  1. M. Floreani
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P. Fossa
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S. Gessi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. L. Mosti
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. P. A. Borea
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. P. Dorigo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to P. Dorigo.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Floreani, M., Fossa, P., Gessi, S. et al. New milrinone analogues: in vitro study of structure-activity relationships for positive inotropic effect, antagonism towards endogenous adenosine, and inhibition of cardiac type III phosphodiesterase. Naunyn-Schmiedeberg's Arch Pharmacol 367, 109–118 (2003). https://doi.org/10.1007/s00210-002-0675-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00210-002-0675-2

Keywords

Search

Navigation